DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy

• Status: Unknown status
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is A Randomized, Double-blind, Placebo-controlled, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects with Benign Masseteric Hypertrophy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A

Criteria

Inclusion Criteria:

1. Male or female subject over 18 years of age and written informed consent is obtained.

2. Subject with Benign Masseter Hypertrophy

3. Subject who has Bisymmetry of masseter at visual assessment.

4. Subjects who meets thickness of Masseter muscle by ultrasonography.

5. Subjects who can and will comply with the requirements of the protocol.

Exclusion Criteria:

1. Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function

2. Subject who got any treatment, including double jaw surgery, laser, thread treatment etc. in 12 months.

3. Subject who had previously received botulinum toxin within 3 months prior to the study entry

4. Subject with known hypersensitivity to botulinum toxin

5. Subject who are pregnant or lactating or found pregnancy though the urine or sebum test or disagreed to avoid pregnancy during study period.

6. Subjects who are not eligible for this study at the discretion of the investigator